Get the Stockscreener App
30.78
0.62%
0.19
After Hours:
30.78
Azenta Inc stock is traded at $30.78, with a volume of 963.49K.
It is up +0.62% in the last 24 hours and up +15.19% over the past month.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.
See More
Previous Close:
$30.59
Open:
$30.43
24h Volume:
963.49K
Relative Volume:
1.14
Market Cap:
$1.39B
Revenue:
$656.32M
Net Income/Loss:
$-164.17M
P/E Ratio:
-10.33
EPS:
-2.9794
Net Cash Flow:
$12.90M
1W Performance:
+5.66%
1M Performance:
+15.19%
6M Performance:
-38.44%
1Y Performance:
-41.51%
1-Day Range:
$29.84
$30.96
1-Week Range:
$29.17
$31.42
52-Week Range:
$23.91
$63.58
Azenta Inc Stock (AZTA) Company Profile
Name
Azenta Inc
Sector
Industry
Phone
(978) 262-2400
Address
200 SUMMIT DRIVE, BURLINGTON
Compare AZTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTA
Azenta Inc
|
30.78 | 1.39B | 656.32M | -164.17M | 12.90M | -2.9794 |
|
ISRG
Intuitive Surgical Inc
|
543.41 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
172.25 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
88.28 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
258.00 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
218.80 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Azenta Inc Stock (AZTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-04-24 | Initiated | Jefferies | Hold |
| Feb-01-24 | Reiterated | B. Riley Securities | Buy |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| May-10-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Feb-09-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-31-22 | Resumed | B. Riley Securities | Buy |
| Mar-21-22 | Initiated | Evercore ISI | Outperform |
View All
Azenta Inc Stock (AZTA) Latest News
Azenta Inc (AZTA) Trading 3.24% Higher on Jun 18 - GuruFocus
Shareholders in Azenta (NASDAQ:AZTA) have lost 59%, as stock drops 3.6% this past week - Yahoo Finance
SG Americas Securities LLC Has $1.07 Million Stock Position in Azenta, Inc. (NASDAQ:AZTA) - Defense World
GAMMA Investing LLC Increases Stake in Azenta, Inc. (NASDAQ:AZTA) - Defense World
California State Teachers Retirement System Sells 5,299 Shares of Azenta, Inc. (NASDAQ:AZTA) - Defense World
Azenta, Inc. (NASDAQ:AZTA) Shares Acquired by Deutsche Bank AG - Defense World
Cetera Investment Advisers Sells 539 Shares of Azenta, Inc. (NASDAQ:AZTA) - Defense World
Millennium Management LLC Purchases 17,899 Shares of Azenta, Inc. (NASDAQ:AZTA) - Defense World
Is Now An Opportune Moment To Examine Azenta, Inc. (NASDAQ:AZTA)? - Yahoo
Azenta, Inc. (NASDAQ:AZTA) Position Lessened by Man Group plc - Defense World
Enhance Laboratory Efficiency with Azenta’s CryoPod Carrier - Lab Manager
Ameriprise Financial Inc. Increases Holdings in Azenta, Inc. (NASDAQ:AZTA) - Defense World
Captrust Financial Advisors Acquires 2,026 Shares of Azenta, Inc. (NASDAQ:AZTA) - Defense World
The Manufacturers Life Insurance Company Has $447,000 Holdings in Azenta, Inc. (NASDAQ:AZTA) - Defense World
Azenta Announces Leadership Change with New General Counsel - TipRanks
Azenta Life Sciences and Form Bio Announce Strategic Partnership - GuruFocus
Northern Trust Corp Reduces Stake in Azenta, Inc. (NASDAQ:AZTA) - Defense World
Azenta (AZTA) Partners with Form Bio to Advance AAV Gene Therapy - GuruFocus
Azenta, Form Bio Launch Partnership for AAV Gene Therapy - marketscreener.com
Azenta Life Sciences And Form Bio Announce Strategic Partnership To Advance AAV Gene Therapy Development - marketscreener.com
Azenta, Form Bio announce strategic partnership - TipRanks
Azenta Life Sciences and Form Bio Announce Strategic Partnership to Advance AAV Gene Therapy Development - Nasdaq
Azenta, Inc. (NASDAQ:AZTA) Shares Sold by Voya Investment Management LLC - Defense World
Waters Corporation, Avantor, Azenta, Bio-Techne, and Elanco Stocks Trade Up, What You Need To Know - Yahoo Finance
Azenta to Participate in the UBS MedTech, Tools and Genomics Summit 2023 - Seeking Alpha
AZTA Q1 Earnings Call: Revenue Tops Expectations, Margin Progress Amid Macro Headwinds - FinancialContent
Price T Rowe Associates Inc. MD Increases Stock Holdings in Azenta, Inc. (NASDAQ:AZTA) - The AM Reporter
Needham & Company LLC Lowers Azenta (NASDAQ:AZTA) Price Target to $40.00 - Defense World
Balance Sheet Insights: Azenta Inc (AZTA)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Azenta targets 3%-5% organic growth and expands automation initiatives for FY2025 - MSN
Azenta, Inc. (NASDAQ:AZTA) Q2 2025 Earnings Call Transcript - Insider Monkey
First Trust Advisors LP Buys New Stake in Azenta, Inc. (NASDAQ:AZTA) - Defense World
Azenta Inc (AZTA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Macroeconomic ... - Yahoo
Azenta (NASDAQ:AZTA) Hits New 1-Year Low Following Weak Earnings - Defense World
Azenta Inc (AZTA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Macroeconomic Challenges - GuruFocus
Azenta, Inc. Reports Solid Q2 2025 Revenue Growth - TipRanks
Azenta, Inc. Reports Strong Q2 2025 Earnings - TipRanks
Azenta (AZTA) Price Target Lowered by Needham to $40 | AZTA Stoc - GuruFocus
Azenta Q2 2025 slides: Revenue growth returns with 400 bps margin expansion By Investing.com - Investing.com South Africa
Azenta (AZTA) Price Target Lowered by Needham to $40 | AZTA Stock News - GuruFocus
Transcript : Azenta, Inc., Q2 2025 Earnings Call, May 07, 2025 - marketscreener.com
Needham Adjusts Price Target on Azenta to $40 From $59, Keeps Buy Rating - marketscreener.com
Earnings call transcript: Azenta’s Q2 2025 results miss EPS forecast, stock rises - Investing.com Australia
Azenta Q2 2025 slides: Revenue growth returns with 400 bps margin expansion - Investing.com India
Azenta Fiscal Q2 Non-GAAP Earnings Fall, Revenue Rises - marketscreener.com
Azenta Surpasses Revenue Expectations in Q1 CY2025News and Statistics - IndexBox
Azenta (NASDAQ:AZTA) Beats Q1 Sales Targets - FinancialContent
Azenta (AZTA) Reports Q2 Earnings with Revenue Decline - GuruFocus
Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025 | AZTA Stock News - GuruFocus
Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025 - Quantisnow
Azenta expands PCR plate range - European Pharmaceutical Manufacturer
Azenta Inc Stock (AZTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Azenta Inc Stock (AZTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zhou Ginger | SVP and General Manager, Genom |
Jan 31 '25 |
Buy |
45.88 |
417 |
19,132 |
27,916 |
| Pirogova Olga | SVP and CHRO |
Nov 19 '24 |
Sale |
40.07 |
548 |
21,958 |
19,373 |
| Hughes Violetta | VP, Chief Accounting Officer |
Nov 19 '24 |
Sale |
40.07 |
163 |
6,531 |
9,920 |
| Zhou Ginger | SVP and General Manager, Genom |
Nov 19 '24 |
Sale |
40.07 |
491 |
19,674 |
27,499 |
| Wang David Dong | SVP & GM, SMS |
Nov 19 '24 |
Sale |
40.07 |
348 |
13,944 |
24,114 |
| Joseph Jason | SVP, General Counsel, Secy. |
Nov 19 '24 |
Sale |
40.07 |
1,139 |
45,640 |
112,564 |
| Cueto Herman | EVP, Chief Financial Officer |
Nov 19 '24 |
Sale |
40.07 |
712 |
28,530 |
23,892 |
| Marotta John | President and CEO |
Nov 18 '24 |
Buy |
39.48 |
12,717 |
502,066 |
99,612 |
| Marotta John | President and CEO |
Nov 19 '24 |
Buy |
40.67 |
1,250 |
50,838 |
100,862 |
| Cornog William L | Director |
Nov 18 '24 |
Buy |
39.60 |
12,500 |
495,000 |
14,755 |
0.50%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):